GIP and obesity due to melanocortin 4 receptor deficiency: One of the most promising advancements in diabetes treatment is the emergence of dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists, commonly referred to as “twincretins.” These agents represent a novel therapeutic approach for managing T2D and obesity.